Skip to content

Kodiak Sciences Inc KOD Stock-Based Comp

Stock-Based Comp at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$257.4M+0.7%
HRO
HarrowHROW
$3.84M-15.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$13.39M+31.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$15.58M+49.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$8.75M+29.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$13.21M+70.6%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's stock-based comp?
Kodiak Sciences Inc (KOD) reported stock-based comp of $12.16M in Q1 2026.
How has Kodiak Sciences Inc's stock-based comp changed year-over-year?
Kodiak Sciences Inc's stock-based comp decreased by 23.5% year-over-year, from $15.89M to $12.16M.
What is the long-term trend for Kodiak Sciences Inc's stock-based comp?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's stock-based comp has grown at a -1.0% compound annual growth rate (CAGR), from $61.39M to $58.86M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.